Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Not Yet Opened 04-06 16:00:00 EDT

1.10

+0.03

+2.80%

盘后1.10

+0.000.00%

19:53 EDT

High1.12	Low1.05	Vol633.74K
Open1.07	D1 Closing1.07	Amplitude6.54%
Mkt Cap32.21M	Tradable Cap27.71M	Total Shares29.28M
T/O685.02K	T/O Rate2.52%	Tradable Shares25.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":1.1,"timestamp":1775505600000,"preClose":1.07,"halted":0,"volume":633742,"hourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"19:53 EDT","volume":4514,"amount":4956.3932,"timestamp":1775519589220,"change":0,"changeRate":0,"amplitude":0.027273},"delay":0,"changeRate":0.028037383177570117,"floatShares":25187700,"shares":29281100,"eps":-1.29172,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"04-06 16:00:00 EDT","open":1.07,"high":1.12,"low":1.05,"amount":685020.0298202,"amplitude":0.065421,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.29172,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":0,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":1.07,"preHourTrading":{"tag":"盘前","latestPrice":1.07,"preClose":1.07,"latestTime":"09:27 EDT","volume":29427,"amount":30876.2267814,"timestamp":1775482070544,"change":0,"changeRate":0,"amplitude":0.056075},"postHourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"19:53 EDT","volume":4514,"amount":4956.3932,"timestamp":1775519589220,"change":0,"changeRate":0,"amplitude":0.027273},"volumeRatio":0.735206},"requestUrl":"/m/hq/s/LGVN/tweets","defaultTab":"tweets","newsList":[{"id":"2622000753","title":"Longeveron Receives Extended Nasdaq Compliance Grace Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000753?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:46","pubTimestamp":1774471612,"startTime":"0","endTime":"0","summary":"Longeveron ( ($LGVN) ) has shared an update. On September 22, 2025, Longeveron Inc. disclosed it had fallen out of compliance with Nasdaq’s $1.00 m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-receives-extended-nasdaq-compliance-grace-period?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-receives-extended-nasdaq-compliance-grace-period?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NQmain","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004323","title":"Longeveron gains Nasdaq extension; minimum bid compliance deadline moves to September 21, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004323","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004323?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:01","pubTimestamp":1774468877,"startTime":"0","endTime":"0","summary":"Nasdaq notified Longeveron that it was not in compliance with the $1.00 minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days.The company received an additional 180-day compliance period, extending the deadline to September 21, 2026.Nasdaq said compliance can be regained if the closing bid price is at least $1.00 for at least 10 consecutive business days.The notice did not immediately affect the stock’s listing status on the Nasdaq Capital Market.Longeveron said it is evaluating options to regain compliance, including a potential reverse stock split.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via EDGAR, the El","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLvq6hT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622082013","title":"Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2622082013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622082013?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:38","pubTimestamp":1774384716,"startTime":"0","endTime":"0","summary":"Longeveron ( ($LGVN) ) has issued an update. On March 23, 2026, Longeveron Inc. cancelled a special meeting of stockholders that had been scheduled...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-cancels-special-meeting-reschedules-reverse-split-vote?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-cancels-special-meeting-reschedules-reverse-split-vote?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620199082","title":"Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2620199082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620199082?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:00","pubTimestamp":1773900051,"startTime":"0","endTime":"0","summary":"Longeveron Inc. (LGVN) has disclosed a new risk, in the Innovation / R&D category. Longeveron Inc. faces elevated uncertainty in its Alzheimer’s di...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeverons-alzheimers-program-faces-high-late-stage-failure-risk-and-potential-pipeline-pressure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeverons-alzheimers-program-faces-high-late-stage-failure-risk-and-potential-pipeline-pressure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SSI","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620991532","title":"Longeveron Earnings Call: Pivotal Trials, Tight Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2620991532","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620991532?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:04","pubTimestamp":1773878655,"startTime":"0","endTime":"0","summary":"Longeveron Inc. (($LGVN)) has held its Q4 earnings call. Read on for the main highlights of the call. Longeveron’s latest earnings call blended not...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-earnings-call-pivotal-trials-tight-cash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-earnings-call-pivotal-trials-tight-cash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620296671","title":"Longeveron price target lowered to $2 from $3 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620296671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620296671?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:20","pubTimestamp":1773876016,"startTime":"0","endTime":"0","summary":"Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $2 from $3 but keeps a Buy rating on the shares. The firm continues to expect ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-price-target-lowered-to-2-from-3-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-price-target-lowered-to-2-from-3-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620086414","title":"Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620086414","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620086414?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:08","pubTimestamp":1773778117,"startTime":"0","endTime":"0","summary":"Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 30.6 percent. This is a 18.52 percent increase over losses of $(0.27) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51310672/longeveron-q4-eps-0-22-beats-0-32-estimate-sales-365-000k-beat-148-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620408109","title":"Longeveron Announces 2025 Full Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620408109","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620408109?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257647/0/en/Longeveron-Announces-2025-Full-Year-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","JPO","BK4585","BK4150","IND","BK4139","MSC","BK4588","BK4528","BK4613","SAP","BK4023","BK4132","AD","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620820408","title":"Longeveron FY 2025 net loss widened 41% to USD 22.7 million as revenue fell 50% to USD 1.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620820408","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620820408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:02","pubTimestamp":1773777760,"startTime":"0","endTime":"0","summary":"Longeveron published its annual report on Form 10-K for the year ended Dec. 31, 2025. Revenue fell 50% to USD 1.2 million, reflecting lower participant demand for its Bahamas Registry Trial and reduced demand for contract manufacturing services. Net loss widened 41% to USD 22.7 million. Research and development expense rose 48% to USD 12.04 million, driven by higher personnel costs and increased CMC spending tied to technology transfer and BLA-enabling efforts. The company said cash and cash equivalents of USD 4.7 million as of Dec. 31, 2025, together with USD 15.9 million in gross proceeds from a March 2026 private placement, are expected to fund operations into the fourth quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL1sbKt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620315470","title":"Longeveron Braces For Q4 Results Following Recent Funding Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2620315470","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620315470?lang=en_us&edition=fundamental","pubTime":"2026-03-18 03:16","pubTimestamp":1773774960,"startTime":"0","endTime":"0","summary":"Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/17/Gloves--Test-And-Doctor-With-Medicine--S.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/17/Gloves--Test-And-Doctor-With-Medicine--S.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51308659/longeveron-braces-for-q4-results-following-recent-funding-boost","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51308659/longeveron-braces-for-q4-results-following-recent-funding-boost","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LGVN","RSI","BK4150","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619416621","title":"Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO Stephen H. Willard","url":"https://stock-news.laohu8.com/highlight/detail?id=2619416621","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619416621?lang=en_us&edition=fundamental","pubTime":"2026-03-14 08:59","pubTimestamp":1773449969,"startTime":"0","endTime":"0","summary":"Longeveron Inc. filed an initial statement of beneficial ownership  naming Willard Stephen H as Chief Executive Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260314:nNDL8lRyJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618321561","title":"Longeveron Inc. to report full-year 2025 financial results and host conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2618321561","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618321561?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:05","pubTimestamp":1773320742,"startTime":"0","endTime":"0","summary":"Longeveron will report full-year 2025 financial results on March 17, 2026 after the U.S. financial markets close. The company will host a conference call and webcast on March 17, 2026 at 4:30 p.m. ET, accessible via Click Here. A “Call me” registration link is available at Click Here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL3Cnkly:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","BK4588","BK4139","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","BK4112","SG9999014021.USD","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618997308","title":"Longeveron closes USD 15 million private placement of shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618997308","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618997308?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:18","pubTimestamp":1773260288,"startTime":"0","endTime":"0","summary":"Longeveron closed a private placement for up to USD 30 million in gross proceeds, priced at-the-market under Nasdaq rules. The initial closing raised about USD 15 million in gross proceeds, led by Coastlands Capital with participation from Janus Henderson Investors. Longeveron issued 6.01 million Class A shares at USD 0.52 per share and Series A non-voting convertible preferred stock convertible into 22.83 million Class A shares. The company may receive up to an additional USD 15 million in gross proceeds subject to milestone-driven conditions tied to its Phase 2b ELPIS II trial in HLHS and share price. Longeveron also agreed to sell investors an interest in 50% of proceeds from any future sale of a Rare Pediatric Disease Priority Review Voucher related to its HLHS program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6nwC9W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4135","IE00BGHQF748.EUR","IE00B64PRP62.GBP","JHG","IE00B3QW5Z07.USD","BK4139","LU0054578231.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618739449","title":"Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618739449","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618739449?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259500,"startTime":"0","endTime":"0","summary":"-- $15 million upfront with a milestone-driven potential additional $15. million related to the Company's anticipated pivotal clinical trial in. Hypoplastic Left Heart Syndrome  priced at the market under Nasdaq. -- Private placement led by Coastlands Capital with participation from Janus. -- Initial proceeds extend cash runway into 4Q26, past the anticipated. pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement was led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million.H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory development of laromestrocel, working capital and other general corporate purposes. B","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4150","BK4132","BK4022","MSC","LGVN","AD","BK4232","BK4575","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618892538","title":"3 Penny Stocks to Watch Now, 3/11/26","url":"https://stock-news.laohu8.com/highlight/detail?id=2618892538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618892538?lang=en_us&edition=fundamental","pubTime":"2026-03-11 22:11","pubTimestamp":1773238260,"startTime":"0","endTime":"0","summary":"Agape ATP ($ATPC), Longeveron ($LGVN), and MiNK Therapeutics ($INKT) are the 3 Penny Stocks to watch on March 11, based on TipRanks’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-3-11-26?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-3-11-26?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4175","ATPC","LGVN","BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618095537","title":"Longeveron prices 6.01M shares at 52c in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618095537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618095537?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:16","pubTimestamp":1773148569,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) entered into a definitive agreement with certain institutional and accredited investors for up to approximately $30M in gross pro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-prices-6-01m-shares-at-52c-in-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-prices-6-01m-shares-at-52c-in-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953902","title":"Press Release: Longeveron Announces Private Placement of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953902?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:01","pubTimestamp":1773147660,"startTime":"0","endTime":"0","summary":"-- $15 million upfront with a milestone-driven potential additional $15. million related to the Company's anticipated pivotal clinical trial in. Hypoplastic Left Heart Syndrome  priced at the market under Nasdaq. -- Private placement led by Coastlands Capital with participation from Janus. -- Initial proceeds extend cash runway into 4Q26, past the anticipated. pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million.H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MSC","LGVN","R","AD","BK4132","BK4150","BK4022","BK4232","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614031808","title":"Longeveron reports Phase 2b trial results showing laromestrocel improves age-related frailty in Cell Stem Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2614031808","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614031808?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:05","pubTimestamp":1772035512,"startTime":"0","endTime":"0","summary":"Longeveron Inc. reported that results from its Phase 2b randomized, dose-finding clinical trial of intravenous laromestrocel , an investigational allogeneic mesenchymal stem cell therapy, were published in the journal Cell Stem Cell. The study  enrolled 148 ambulatory individuals with age-related frailty and evaluated physical functioning and patient-reported outcomes. Longeveron stated that laromestrocel was associated with dose- and time-dependent increases in the 6-minute walk test compared with placebo, including a 63.4-meter improvement at month 9 , and reported associations with PROMIS Physical Function scores and changes in soluble TIE-2 as a potential biomarker. The results have already been presented in the form of a peer-reviewed publication.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL4NQXRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","SG9999014005.SGD","LGVN","LU2095319765.USD","LU2210150020.SGD","BK4585","SG9999014021.USD","NDAQ","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","LU2210149790.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614318320","title":"Longeveron® Results of Phase 2B Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients With Age-Related Frailty Published in Cell Stem Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2614318320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614318320?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:05","pubTimestamp":1772035500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUABV2H8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611196210","title":"Longeveron Appoints New CEO Amid Cost-Cutting Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2611196210","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611196210?lang=en_us&edition=fundamental","pubTime":"2026-02-14 06:23","pubTimestamp":1771021404,"startTime":"0","endTime":"0","summary":"Longeveron ( ($LGVN) ) has provided an update. On February 9, 2026, interim CEO Than Powell resigned from his temporary role at Longeveron but rema...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-appoints-new-ceo-amid-cost-cutting-initiatives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-appoints-new-ceo-amid-cost-cutting-initiatives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","US2Y.BOND","US30Y.BOND","BK4096","US3Y.BOND","TLTW","BK4585","US10Y.BOND","TMF","US7Y.BOND","US5Y.BOND","BK4588","US12M.BOND","US6M.BOND","LGVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":0.1823},{"period":"1month","weight":1.2746},{"period":"3month","weight":0.8755},{"period":"6month","weight":0.1864},{"period":"1year","weight":-0.2143},{"period":"ytd","weight":1.1739}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052773},{"month":3,"riseRate":0.5,"avgChangeRate":0.193379},{"month":4,"riseRate":0.5,"avgChangeRate":-0.103235},{"month":5,"riseRate":0.4,"avgChangeRate":-0.141174},{"month":6,"riseRate":0.8,"avgChangeRate":0.122312},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}